Рынок острого коронарного синдрома в Азиатско-Тихоокеанском регионе – тенденции отрасли и прогноз до 2029 года

Анализ и информация о рынке острого коронарного синдрома в Азиатско-Тихоокеанском регионе

Ожидается, что рынок острого коронарного синдрома в Азиатско-Тихоокеанском регионе значительно вырастет в прогнозируемый период с 2022 по 2029 год. По данным Data Bridge Market Research, рынок растет со среднегодовым темпом роста 6,1% в прогнозируемый период с 2022 по 2029 год и, как ожидается, достигнет 3 304,22 млн долларов США к 2029 году. Основными факторами, способствующими росту рынка острого коронарного синдрома, являются рост распространенности хронических заболеваний, таких как ишемическая болезнь сердца, ишемическая болезнь сердца и сосудистые заболевания, рост гериатрического населения, широкий ассортимент продукции, предлагаемой участниками рынка, что приведет к росту рынка острого коронарного синдрома в будущем.

Острый коронарный синдром относится к группе заболеваний, при которых снижается приток крови к сердцу. Состояния, связанные с ОКС, включают инфаркт миокарда с подъемом сегмента ST (ИМСПST), инфаркт миокарда без подъема сегмента ST (ИМБПST) и нестабильную стенокардию. Это тип ишемической болезни сердца (ИБС), который является причиной одной трети всех смертей у людей старше 35 лет. Некоторые формы ИБС могут протекать бессимптомно, но ОКС всегда имеет симптоматику.

Острый коронарный синдром (ОКС) является проявлением ишемической болезни сердца (ИБС) и обычно является результатом разрушения бляшек в коронарных артериях (атеросклероза). Распространенными факторами риска заболевания являются курение, гипертония , диабет, гиперлипидемия, физическая неактивность, ожирение в семье и неправильное питание. Злоупотребление кокаином также может привести к вазоспазму. Семейный анамнез раннего инфаркта миокарда (55 лет) также является фактором высокого риска.

Отчет о рынке острого коронарного синдрома в Азиатско-Тихоокеанском регионе содержит подробную информацию о доле рынка, новых разработках, влиянии внутренних и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов , стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и рыночный сценарий, свяжитесь с нами для получения аналитического обзора, наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели.

Acute Coronary Syndrome Market Dynamics

Drivers

• Rise in Prevalence of Chronic Diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases

As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the U.S., Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of acute coronary syndrome boosts the market growth.

• Growing Geriatric Population

The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in Middle East and Africa& Asia-Pacific region, creates an opportunity for market growth in the forecast period.

• Wide Range of Products Offered by Market Players

Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.

Opportunities

• Surge in Technological Advancements for Cardiovascular Disease

As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the global acute coronary syndrome market in the forecast period.

Also, governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.

Restraints/Challenges

Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are the restrains and challenges for the growth of acute coronary syndrome market.

The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of these product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.

This acute coronary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on acute coronary syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In November 2021, Merck, announced the successful completion of the acquisition of Acceleron Pharma Inc. It is an important and strategic opportunity for company to continue growing their cardiovascular portfolio and pipeline that builds on long and proud legacy in cardiovascular disease and further bolsters company’s business development strategy fueled by Acceleron’s groundbreaking research.

Asia-Pacific Acute Coronary Syndrome Market Scope

Asia-Pacific acute coronary syndrome market is categorized based on type, diagnosis, treatment and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

• Non-St-Elevation Myocardial Infarction
• St-Elevation Myocardial Infarction
• Unstable Angina

On the basis of type, the Asia-Pacific acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.

Diagnosis

• Stress Test
• Blood Tests
• Imaging
• Others

On the basis of diagnosis, the Asia-Pacific acute coronary syndrome market is segmented into stress test, blood test, imagining and others.

Treatment

• Medication
• Surgery

On the basis of treatment, the Asia-Pacific acute coronary syndrome market is segmented into medication and surgery.

End User

• Hospitals and Clinics
• Diagnostic Centers
• Academic Institutes
• Others

On the basis of end user, the Asia-Pacific acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others.

Acute Coronary Syndrome Market Regional Analysis/Insights

Asia-Pacific acute coronary syndrome market is further segmented into major countries including China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific.

China in Asia-Pacific dominates the acute coronary market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the well-developed healthcare infrastructure in the country and increasing patient population.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Acute Coronary Syndrome Market Share Analysis

Asia-Pacific acute coronary syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the Asia-Pacific acute coronary syndrome market.

Some of the major prominent participants operating in the Asia-Pacific acute coronary syndrome market are Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), MYODERM (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and others.

Research Methodology

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Рыночные данные анализируются и оцениваются с использованием рыночных статистических и когерентных моделей. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в рыночном отчете. Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Помимо этого, модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, анализ доли рынка компании, стандарты измерения, глобальный/региональный и анализ доли поставщиков. Пожалуйста, запросите звонок аналитика в случае дальнейшего запроса.

SKU-68013